Company Overview and News

 
Cobalt Miners News For The Month Of April 2018

2018-04-25 seekingalpha
Cobalt miner news - South Korea's LG Chem to set up battery material JVs with China's Zhejiang Huayou Cobalt.
Upvote Downvote

1
A Look At The Junior Cobalt Miners In Early 2018

2018-04-17 seekingalpha
This article first appeared on Trend Investing on February 16, therefore all data is as of that date.
Upvote Downvote

1
Cobalt Miners News For The Month Of March 2018

2018-03-25 seekingalpha
Cobalt spot price news - Spot prices rise 18.7% in the past month as inventory falls. The cobalt spot price is now over USD 40/lb, and approaching USD 100,000/tonne.
Upvote Downvote

4
Cobalt Miners News For The Month Of February 2018

2018-02-23 seekingalpha
Cobalt market news - the DRC to hike taxes on Congo cobalt miners. ERG says "cobalt boom ‘guaranteed’ for 7-10 years."
Upvote Downvote

6
Cobalt Miners News For The Month Of January 2018

2018-01-24 seekingalpha
Cobalt spot price news - Cobalt prices up again in January. "BMO Capital Markets expects current cobalt prices to double in the next two years."
Upvote Downvote

2
Cobalt Miners News For The Month Of December 2017

2017-12-22 seekingalpha
Cobalt market news - "Electric vehicle revolution a rare investment opportunity as metals demand spikes." "BMW sees 10-fold jump in its need for battery materials by 2025."
Upvote Downvote

 
OreCorp pauses trade to digest update from Barrick Gold Corporation in Tanzania

2017-10-20 proactiveinvestors.com.au
OreCorp Ltd (ASX:ORR) has been granted a trading halt by the ASX, pending further information in relation to the recent announcement by Barrick Gold Corporation (NYSE:ABX)(TSX:ABX) and the Government of Tanzania.
Upvote Downvote

 
OreCorp enters capital raising

2017-03-27 proactiveinvestors.com.au
OreCorp (ASX:ORR) has been granted a trading halt by the ASX, pending details of a capital raising.
Upvote Downvote

 
OreCorp reveals robust economics at gold project in Tanzania

2017-03-13 proactiveinvestors.com.au
OreCorp (ASX:ORR) has reported the pre-feasibility study for its Nyanzaga Gold Project in Tanzania, revealing an economically robust project delivering a total of 2.56 million ounces of gold.
Upvote Downvote

 
3 Small Gold Explorers Worth Less Than Their Liquidation Value

2017-01-18 seekingalpha
The 3 companies in this article are worth less than their liquidation value, with assets ranging from cash to shares to JV and exploration properties.
Upvote Downvote

 
3rd Quarter Results

2016-10-21 londonstockexchange
“Our strong third quarter operational and financial results represent another significant step forward for Acacia, particularly  considering some of the headwinds experienced during the quarter”, said Brad Gordon, Chief Executive Officer. “I am particularly pleased with North Mara’s performance this quarter, delivering 112,523 ounces at an all-in sustaining cost (“AISC”) of US$655 per ounce sold. This more than offset the impact of operational stoppages at Bulyanhulu and the deferred access to higher grades at Buzwagi.
Upvote Downvote

 
Trading Halt

2016-05-03 asx.com.au
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...